Background: Individuals aged more than 55 years may be more likely to experience chronic diseases and are treated with multiple concomitant medications. This may result in drug-drug interactions (DDIs) that are often not considered in clinical practice settings. Statins are effective in older patients with or at risk for cardiovascular disease (CVD) and are prescribed on a regular basis for a long term and may undergo DDIs. The risk of DDIs varies among statins, and prevalence and severity levels of statin-drug interactions are important in older patients with chronic conditions on concomitant drugs. Objectives: To evaluate the prevalence and severity of the potential statin-drug interactions among older adult patients (55 years or older) who have received statin therapy at hospital discharge for a period of 18 months from January 2021 to June 2022 in Sana’a city. Methods: This cross-sectional study was conducted in a hospital in Sana’a city from January 2021 to June 2022. Data collection was from the electronic medical records (covering demographic, clinical, and drug-therapy-related variables). The format was also filled with; BP, Sr.cr, HbA1c, HR, Total cholesterol, TG, LDL, HDL, AST, and ALT values for each patient. Drug interactions were identified using both Medscape and Lexicomp software. Results: Out of 200 patients, there were 175 (87.5%) individuals had a total of 865 clinically significant drug-drug interactions. specifically speaking, 55 (27.5%) individuals had a total of 72 clinically significant statin-drug interactions. 57 (79.1%) of which were category C, 14 (19.44%) of which were category D, and only 1 (1.39%) category X statin-drug interaction. There was also an association between advanced age, co-morbidities, and concomitant drugs with the presence of statin-drug interaction. Conclusion: It can be concluded from this study, that statin medications have a significant prevalence among elderlies due to the presence of multiple co-morbidities and subsequently the concomitant use of multiple medications. It was also noticed that category C statin-drug interactions were the most common and then followed by category D statin-drug interactions.
{"title":"Evaluating the Potential Statin-Drug Interactions among Older Patients with Chronic Diseases in Sana’a City, Yemen","authors":"Ali Alyahawi","doi":"10.23880/apct-16000209","DOIUrl":"https://doi.org/10.23880/apct-16000209","url":null,"abstract":"Background: Individuals aged more than 55 years may be more likely to experience chronic diseases and are treated with multiple concomitant medications. This may result in drug-drug interactions (DDIs) that are often not considered in clinical practice settings. Statins are effective in older patients with or at risk for cardiovascular disease (CVD) and are prescribed on a regular basis for a long term and may undergo DDIs. The risk of DDIs varies among statins, and prevalence and severity levels of statin-drug interactions are important in older patients with chronic conditions on concomitant drugs. Objectives: To evaluate the prevalence and severity of the potential statin-drug interactions among older adult patients (55 years or older) who have received statin therapy at hospital discharge for a period of 18 months from January 2021 to June 2022 in Sana’a city. Methods: This cross-sectional study was conducted in a hospital in Sana’a city from January 2021 to June 2022. Data collection was from the electronic medical records (covering demographic, clinical, and drug-therapy-related variables). The format was also filled with; BP, Sr.cr, HbA1c, HR, Total cholesterol, TG, LDL, HDL, AST, and ALT values for each patient. Drug interactions were identified using both Medscape and Lexicomp software. Results: Out of 200 patients, there were 175 (87.5%) individuals had a total of 865 clinically significant drug-drug interactions. specifically speaking, 55 (27.5%) individuals had a total of 72 clinically significant statin-drug interactions. 57 (79.1%) of which were category C, 14 (19.44%) of which were category D, and only 1 (1.39%) category X statin-drug interaction. There was also an association between advanced age, co-morbidities, and concomitant drugs with the presence of statin-drug interaction. Conclusion: It can be concluded from this study, that statin medications have a significant prevalence among elderlies due to the presence of multiple co-morbidities and subsequently the concomitant use of multiple medications. It was also noticed that category C statin-drug interactions were the most common and then followed by category D statin-drug interactions.","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124568056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neuroprotective effect of Crocin against intracerebral administration of Colchicine induced neurotoxicity in mice has been studied. Effect of Crocin on colchicine induced memory impairment in Morris water maze test was done. Colchicine is a powerful mitotic poison, anti-inflammatory, and inhibitor of tumor growth. Most biological effects of colchicine are probably related to the formation of a colchicine-tubulin complex which prevents microtubule polymerization. It is used in cancer chemo therapy but is limited due to its high toxicity. The present study showed that intraperitoneal administration of Crocin has neuroprotective effect. It was suggested because of assessing various biochemical and behavioural parameters. In this study two models were taken (colchicine and aluminium chloride induced oxidative damage and cognitive dysfunction) to assess neuroprotective effect of crocin. Neuroprotective action of crocin may be beneficial for the prevention and treatment of Al-induced oxidative damage in the brain. The present study also showed that treatment with crocin ameliorated colchicine-induced memory impairment in mice. Furthermore, the beneficial effects of crocin may be attributed to reduced oxidative stress and cholinergic dysfunction in the brain.
{"title":"To Investigate the Neuroprotective Effect of Crocin against Colchicine and Aluminium Chloride Induced Cognitive Disfunction and Oxidative Damage in Rodents","authors":"Parul Sharma","doi":"10.23880/apct-16000163","DOIUrl":"https://doi.org/10.23880/apct-16000163","url":null,"abstract":"Neuroprotective effect of Crocin against intracerebral administration of Colchicine induced neurotoxicity in mice has been studied. Effect of Crocin on colchicine induced memory impairment in Morris water maze test was done. Colchicine is a powerful mitotic poison, anti-inflammatory, and inhibitor of tumor growth. Most biological effects of colchicine are probably related to the formation of a colchicine-tubulin complex which prevents microtubule polymerization. It is used in cancer chemo therapy but is limited due to its high toxicity. The present study showed that intraperitoneal administration of Crocin has neuroprotective effect. It was suggested because of assessing various biochemical and behavioural parameters. In this study two models were taken (colchicine and aluminium chloride induced oxidative damage and cognitive dysfunction) to assess neuroprotective effect of crocin. Neuroprotective action of crocin may be beneficial for the prevention and treatment of Al-induced oxidative damage in the brain. The present study also showed that treatment with crocin ameliorated colchicine-induced memory impairment in mice. Furthermore, the beneficial effects of crocin may be attributed to reduced oxidative stress and cholinergic dysfunction in the brain.","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115467601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vitamin D3 reported having many important roles in bone metabolism, osteoporosis, immunity, and useful in numerous diseases, i.e., cardiovascular, cancers, and neurodegenerative diseases. Unexpectedly, there is little information available about the concentration of 25-hydroxyvitamin D3 in the blood, which is the best indicator of vitamin D3 status after its oral absorption. However, the biological activity of vitamin D3 is mediated via the formation of the active metabolite, 1-α, 25-dihydroxyvitamin D3 . There are several factors that affect its absorption and first-pass metabolism that lead to having very low plasma concentrations of both the metabolites (25-hydroxyvitamin D3 and 1-α, 25-dihydroxyvitamin D3 ) following an oral administration. Thus, the current study was executed to determine the influence of the Trivedi Effect®-Consciousness Energy Treatment on vitamin D3 and rats through the measurement of plasma 25-hydroxyvitamin D3 concentrations after the oral administration of vitamin D3 in male Sprague-Dawley rats. The test item, vitamin D3 was divided into two parts. One part was denoted as the control (without Biofield Energy Treatment/Blessing), while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Treatment by renowned Biofield Energy Healer, Dahryn Trivedi. Additionally, one group of animals also received Consciousness Energy Treatment per se by the Healer under similar conditions. The Biofield Energy Healer who was located in the USA, while the test samples and animals were located in the research laboratory in India. Vitamin D3 oral formulations were administrated by oral gavage at a dose of 500 µg per kg in groups viz. G1 (untreated vitamin D3 ), G2 (Biofield Treated vitamin D3 ), and G3 (Biofield Treated animals received untreated vitamin D3 ) group. The Biofield Energy Treatment increased the maximum plasma concentration (Cmax) of 25-hydroxyvitamin D3 by 3.45% and 72.77% in the G2 and G3 groups, respectively as compared with the G1 group. The area under the plasma concentration– time curve (AUC0–t) of 25-hydroxyvitamin D3 was altered by -11.19% in the G2 group and 59.45% in the G3 group as compared to the G1 group. After oral administration, the Tmax of 25-hydroxyvitamin D3 was altered by -62.97% in G2 and 55.56% in G3 groups compared to G1. The mean residence time (MRT) of 25-hydroxyvitamin D3 was also altered in the G2 group by -12.34% and G3 group by 0.18%, as compared to the G1. The relative oral bioavailability (Fr) of 25-hydroxyvitamin D3 was significantly altered by -11.19% in the G2 group and 59.45% in the G3 group compared to the G1. Biofield Energy Treatment could be an innovative strategy that opens new avenues to overcome poorly absorbed pharmaceuticals/ nutraceuticals/herbal extracts and can also improve the therapeutic performance of orally active molecules.
{"title":"Influence of the Biofield Energy Treatment on the Pharmacokinetics of 25-Hydroxyvitamin D3 in Male Sprague-Dawley Rats after a Single Oral Dose of Vitamin D3","authors":"S. Jana","doi":"10.23880/apct-16000190","DOIUrl":"https://doi.org/10.23880/apct-16000190","url":null,"abstract":"Vitamin D3 reported having many important roles in bone metabolism, osteoporosis, immunity, and useful in numerous diseases, i.e., cardiovascular, cancers, and neurodegenerative diseases. Unexpectedly, there is little information available about the concentration of 25-hydroxyvitamin D3 in the blood, which is the best indicator of vitamin D3 status after its oral absorption. However, the biological activity of vitamin D3 is mediated via the formation of the active metabolite, 1-α, 25-dihydroxyvitamin D3 . There are several factors that affect its absorption and first-pass metabolism that lead to having very low plasma concentrations of both the metabolites (25-hydroxyvitamin D3 and 1-α, 25-dihydroxyvitamin D3 ) following an oral administration. Thus, the current study was executed to determine the influence of the Trivedi Effect®-Consciousness Energy Treatment on vitamin D3 and rats through the measurement of plasma 25-hydroxyvitamin D3 concentrations after the oral administration of vitamin D3 in male Sprague-Dawley rats. The test item, vitamin D3 was divided into two parts. One part was denoted as the control (without Biofield Energy Treatment/Blessing), while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Treatment by renowned Biofield Energy Healer, Dahryn Trivedi. Additionally, one group of animals also received Consciousness Energy Treatment per se by the Healer under similar conditions. The Biofield Energy Healer who was located in the USA, while the test samples and animals were located in the research laboratory in India. Vitamin D3 oral formulations were administrated by oral gavage at a dose of 500 µg per kg in groups viz. G1 (untreated vitamin D3 ), G2 (Biofield Treated vitamin D3 ), and G3 (Biofield Treated animals received untreated vitamin D3 ) group. The Biofield Energy Treatment increased the maximum plasma concentration (Cmax) of 25-hydroxyvitamin D3 by 3.45% and 72.77% in the G2 and G3 groups, respectively as compared with the G1 group. The area under the plasma concentration– time curve (AUC0–t) of 25-hydroxyvitamin D3 was altered by -11.19% in the G2 group and 59.45% in the G3 group as compared to the G1 group. After oral administration, the Tmax of 25-hydroxyvitamin D3 was altered by -62.97% in G2 and 55.56% in G3 groups compared to G1. The mean residence time (MRT) of 25-hydroxyvitamin D3 was also altered in the G2 group by -12.34% and G3 group by 0.18%, as compared to the G1. The relative oral bioavailability (Fr) of 25-hydroxyvitamin D3 was significantly altered by -11.19% in the G2 group and 59.45% in the G3 group compared to the G1. Biofield Energy Treatment could be an innovative strategy that opens new avenues to overcome poorly absorbed pharmaceuticals/ nutraceuticals/herbal extracts and can also improve the therapeutic performance of orally active molecules.","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124860876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"DNA Binding Potential and Antibacterial Activity of Metamizole","authors":"M. N. Tazehkand","doi":"10.23880/apct-16000172","DOIUrl":"https://doi.org/10.23880/apct-16000172","url":null,"abstract":"","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125678489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment Gap in Patients with Epilepsy","authors":"D. S","doi":"10.23880/apct-16000203","DOIUrl":"https://doi.org/10.23880/apct-16000203","url":null,"abstract":"","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"163 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114660183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Postmenopausal vaginal bleeding has a sign that should not be Ultrasound imaging has become an effective diagnostic tool of gynecological practice throughout the years. Endometrial diagnosis typically involves invasive investigational approaches. Today, however, with the advent of high-resolution transvaginal ultrasound and Doppler ultrasonography (noninvasive diagnostic tool), has an alternative candidate to replace invasive approaches. But in order to obtain an efficient ultrasound report there has must be unified the terms to define ultrasound diagnosis uterine pathology, and to develop the prediction and diagnosis of endometrial pathology. This problem has solved by The International Endometrial Tumor Analysis (IETA) group. In the present study 120 patients with postmenopausal bleeding have included in the study.
{"title":"Burnside and Correlation Analysis Transition of Body into Postmenopausal Vaginal Bleeding Analysis Sonographic Criteria in Diagnosis of Endometrial Carcinoma Study of Less Sunlight","authors":"R. Hajare","doi":"10.23880/apct-16000181","DOIUrl":"https://doi.org/10.23880/apct-16000181","url":null,"abstract":"Postmenopausal vaginal bleeding has a sign that should not be Ultrasound imaging has become an effective diagnostic tool of gynecological practice throughout the years. Endometrial diagnosis typically involves invasive investigational approaches. Today, however, with the advent of high-resolution transvaginal ultrasound and Doppler ultrasonography (noninvasive diagnostic tool), has an alternative candidate to replace invasive approaches. But in order to obtain an efficient ultrasound report there has must be unified the terms to define ultrasound diagnosis uterine pathology, and to develop the prediction and diagnosis of endometrial pathology. This problem has solved by The International Endometrial Tumor Analysis (IETA) group. In the present study 120 patients with postmenopausal bleeding have included in the study.","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132742739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
As a result of the paradigm shifts in the jobs market of the future, the European education system should reinvent itself in order to foster innovation and to change focus to skill-based learning. One possible way is to combine the use of the digital and online media with the practical work to form the skills required by the digital factory of the future. Another challenge for Europe is to enhance the industrial innovation by tightly coupling the three components of the Knowledge Triangle: the HIGH EDUCATION as knowledge producer, the academic RESEARCH as creativity source, and BUSINESS, with its entrepreneurial spirit. Europe is also facing the loss of its cultural and material identity, inclusive the culture of traditional foods and the endangerment of sustainable food resources.
{"title":"The Knowledge Triangle for Food Innovation by Harnessing the Tradition and Assuring Sustainability KNOWinFOOD Project as a Tool to Educate Students to Obtain Innovative Products Incorporating Bioactive Compounds","authors":"C. Georgescu","doi":"10.23880/apct-16000150","DOIUrl":"https://doi.org/10.23880/apct-16000150","url":null,"abstract":"As a result of the paradigm shifts in the jobs market of the future, the European education system should reinvent itself in order to foster innovation and to change focus to skill-based learning. One possible way is to combine the use of the digital and online media with the practical work to form the skills required by the digital factory of the future. Another challenge for Europe is to enhance the industrial innovation by tightly coupling the three components of the Knowledge Triangle: the HIGH EDUCATION as knowledge producer, the academic RESEARCH as creativity source, and BUSINESS, with its entrepreneurial spirit. Europe is also facing the loss of its cultural and material identity, inclusive the culture of traditional foods and the endangerment of sustainable food resources.","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133422657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This work start after seeing an recent open letter for transparency related production an quality control technique of mRNA vaccine first signed by Tarro G, Luisetto M and Monsellato ML and an editorial recognized by IMA Marijnskaya academy: Graphene and Derivate: Physio-Chemical and Toxicology properties in the mRNA Vaccine Manufacturing Strategy, needed specific proof of absence for the regulatory aspects (accepted for publication). Other relevant evidences related to this topic comes from the work of Giovannini, et al. related Dark field microscope assay of the blood of 1086 symptomatic subjects after vaccination with two types of m-RNA vaccine of great interest on this field also the work of P Campra and Young RO, Young Me Lee or Ki-Yeob J. Observing all this recent evidences the aim of this work is to investigate not only the graphene presence (or not) in vials of mRNA Vaccine but also the self-auto assembly properties of graphene and derivate. This is in order to find relationship in some biotechnological application like m-RNA Vaccine’s large scale production. After a review part an experimental hypothesis project will be submitted to the researcher to produce a global conclusion related the topic investigated. The recent evidences published induced the idea to more deeply study these properties for the clinicotoxicological aspects involved. The pro-coagulant properties of the coronavirus covid-19 Spike Protein are well knower by scientific literature as well as the toxicological profile of the graphene derivate. What can happen if this two substantive can act in patients with platelet disorder in the same time?
这项工作开始于最近由Tarro G、Luisetto M和Monsellato ML首先签署的一封关于mRNA疫苗生产和质量控制技术透明度的公开信，以及IMA Marijnskaya学院认可的一篇社论:石墨烯及其衍生物:mRNA疫苗制造策略中的物理化学和毒理学特性，需要在监管方面提供具体的证据(接受发表)。与本课题相关的其他证据来自Giovannini等人的工作，相关的暗场显微镜对1086名有症状的受试者接种两种在该领域非常感兴趣的m-RNA疫苗后的血液检测，以及P Campra和Young RO的工作。Young Me Lee或Ki-Yeob J.观察所有这些最近的证据，本工作的目的不仅是研究石墨烯在mRNA疫苗小瓶中的存在(或不存在)，而且还研究石墨烯及其衍生物的自组装特性。这是为了在m-RNA疫苗的大规模生产等生物技术应用中找到关系。经过审查部分的实验假设项目将提交给研究人员，以产生与所调查主题相关的全局结论。最近发表的证据促使人们从临床毒理学角度对这些特性进行更深入的研究。科学文献以及石墨烯衍生物的毒理学特征已经为冠状病毒covid-19刺突蛋白的促凝特性所熟知。如果这两种药物同时作用于血小板紊乱患者会发生什么?
{"title":"Self-Assembling Property of Graphene Derivates Chemico-Physical and Toxicological Implication","authors":"Mauro Luisetto","doi":"10.23880/apct-16000206","DOIUrl":"https://doi.org/10.23880/apct-16000206","url":null,"abstract":"This work start after seeing an recent open letter for transparency related production an quality control technique of mRNA vaccine first signed by Tarro G, Luisetto M and Monsellato ML and an editorial recognized by IMA Marijnskaya academy: Graphene and Derivate: Physio-Chemical and Toxicology properties in the mRNA Vaccine Manufacturing Strategy, needed specific proof of absence for the regulatory aspects (accepted for publication). Other relevant evidences related to this topic comes from the work of Giovannini, et al. related Dark field microscope assay of the blood of 1086 symptomatic subjects after vaccination with two types of m-RNA vaccine of great interest on this field also the work of P Campra and Young RO, Young Me Lee or Ki-Yeob J. Observing all this recent evidences the aim of this work is to investigate not only the graphene presence (or not) in vials of mRNA Vaccine but also the self-auto assembly properties of graphene and derivate. This is in order to find relationship in some biotechnological application like m-RNA Vaccine’s large scale production. After a review part an experimental hypothesis project will be submitted to the researcher to produce a global conclusion related the topic investigated. The recent evidences published induced the idea to more deeply study these properties for the clinicotoxicological aspects involved. The pro-coagulant properties of the coronavirus covid-19 Spike Protein are well knower by scientific literature as well as the toxicological profile of the graphene derivate. What can happen if this two substantive can act in patients with platelet disorder in the same time?","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128043210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular Identification of Lactic Acid Bacteria Isolated From Regional Yoghurt Samples of Bangladesh Using 16S Rdna Sequencing","authors":"Mahbubur Rahman SM","doi":"10.23880/apct-16000158","DOIUrl":"https://doi.org/10.23880/apct-16000158","url":null,"abstract":"","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121581884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
m RNA VACCINE production like other biopharmaceutical need various purification stages in the manifacturing process. In this process are used techniques like: (TFF) tangential flow filtration followed by different chromatographic procedure (affinity and ion exchange separation) with various kinds of resin and then UF/DF technique (Ultrafiltration-diafiltration). So it is of interest to verify that the materials used for this kind of procedure is solid phases or for the membrane and if released impurity in the final product. For Silica-based Reversed-Phase packing’s, a carbon load percentage indicates the amount of functional bonded phase attached to the Silica-base material. Aim of this work is to investigate the role played by these characteristics in the separation process of mRNA. Because this parameter influence the retention time it is interesting to evaluate the use in separation technique of biopharmaceuticals and this also is for the carbon coated silica columns. Silica gel for chromatography can be produced by systemic process but also form Rice treated at high temperature. What kind of effect can be played using an high level of carbon coated silica material on the final purified product? The graphitic particle can be found as impurity during the manufacturing process of these resins? And what is the role played by carbon (graphene-quantum dots) membrane as reported in various research application?
{"title":"mRNA Purification: Technology Aspects and Impurities TFF, Chromatography, UF/DF (Resins, Magnetic Beads, Monoliths)","authors":"M. Luisetto","doi":"10.23880/apct-16000207","DOIUrl":"https://doi.org/10.23880/apct-16000207","url":null,"abstract":"m RNA VACCINE production like other biopharmaceutical need various purification stages in the manifacturing process. In this process are used techniques like: (TFF) tangential flow filtration followed by different chromatographic procedure (affinity and ion exchange separation) with various kinds of resin and then UF/DF technique (Ultrafiltration-diafiltration). So it is of interest to verify that the materials used for this kind of procedure is solid phases or for the membrane and if released impurity in the final product. For Silica-based Reversed-Phase packing’s, a carbon load percentage indicates the amount of functional bonded phase attached to the Silica-base material. Aim of this work is to investigate the role played by these characteristics in the separation process of mRNA. Because this parameter influence the retention time it is interesting to evaluate the use in separation technique of biopharmaceuticals and this also is for the carbon coated silica columns. Silica gel for chromatography can be produced by systemic process but also form Rice treated at high temperature. What kind of effect can be played using an high level of carbon coated silica material on the final purified product? The graphitic particle can be found as impurity during the manufacturing process of these resins? And what is the role played by carbon (graphene-quantum dots) membrane as reported in various research application?","PeriodicalId":313915,"journal":{"name":"Advances in Pharmacology & Clinical Trials","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115408228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：